CorTec announced on April 23 that its Brain Interchange system has been accepted into the FDA’s Total Product Life Cycle Advisory Program, known as TAP — a dedicated regulatory track reserved for a limited number of breakthrough medical technologies. The decision arrives two weeks after the Freiburg-based company received FDA Breakthrough Device Designation for the same device in stroke motor rehabilitation, the first BCI to hold that designation for a recovery indication rather than communication or paralysis. CorTec is now among a very small group of neurotech companies holding both recognitions.
TAP matters more than the Breakthrough label it follows. Breakthrough Device Designation accelerates a specific device through the existing clearance pathway. TAP is a structural commitment: a dedicated FDA liaison assigned to the programme, accelerated feedback on study design and regulatory strategy, and — critically — early engagement with payers and clinicians, including the Centers for Medicare and Medicaid Services. That last element is the one to watch. No invasive BCI has a clear United States reimbursement pathway today, and no regulatory route to one without CMS at the table. TAP puts CMS at the table.
What TAP actually gives CorTec
The programme is designed to collapse the time between breakthrough designation and routine clinical use by running regulatory dialogue, evidence generation, and reimbursement conversations in parallel rather than serially. For a device class that has historically cleared the FDA only to stall on coverage, this matters. Neuralink, Synchron, Blackrock Neurotech, and now CorTec all hold Breakthrough designations; none has resolved the reimbursement question. TAP is the FDA’s admission that the regulatory bottleneck for implanted BCIs is no longer purely safety or efficacy — it is the downstream economics. An FDA-approved device that no payer covers is an FDA-approved device that no patient receives.
Dr Frank Desiere, CorTec’s chief executive, framed the acceptance as a competitive signal: “TAP acceptance places CorTec at the forefront of a field dominated by US players.” The observation is worth taking at face value. CorTec remains the only European company with an FDA-authorised clinical evaluation of a fully implantable bidirectional BCI running on US soil. Its Breakthrough designation earlier this month was the first globally for stroke motor rehabilitation as an indication. The TAP acceptance extends that lead into the regulatory-access layer.
The clinical base
Brain Interchange is a wireless, closed-loop system that reads cortical activity and delivers targeted stimulation to drive neuroplasticity in stroke patients whose motor recovery has plateaued. The device is a direct attempt at repair rather than bypass — the dominant approach in the broader BCI field, which routes around damaged circuitry rather than attempting to restore it.
CorTec confirmed alongside the TAP announcement that a third patient has now been implanted at Harborview Medical Center in Seattle, bringing the NIH-funded, FDA-approved trial to three participants across a broader range of stroke profiles. An earlier patient has logged nine months of stable wireless performance with both neural sensing and cortical stimulation fully functional throughout. The trial, led by Jeffrey Ojemann at the University of Washington with Steven Cramer at UCLA as co-investigator, is the evidence base CorTec will be bringing into every TAP conversation.
The regulatory calculus
The FDA is now building programme infrastructure specifically for implanted BCIs, not just managing them through existing 510(k) and PMA pathways. That shifts the calculus for any company considering a BCI product: the pathway is becoming visible rather than bespoke. Reimbursement is now an explicit regulatory-stage conversation, not a post-clearance afterthought. Companies waiting until after FDA approval to start CMS dialogue are behind the curve CorTec just got onto. The European regulatory-access premium that many medtech strategies assume — that US clearance is easier than EU clearance for novel implantables — is being compressed by programmes like TAP, which narrow the gap for companies operating dual-market strategies.
For a field that has spent the past eighteen months dominated by US-based competition, the signal from Freiburg is that regulatory geography is not destiny. Execution, evidence, and the willingness to engage with the reimbursement layer early are starting to count more than headquarters location.